source
- Atea’s hepatitis C asset matches Gilead’s Epclusa in phase 3 trialAtea Pharmaceuticals’ hepatitis C prospect has matched Gilead’s Epclusa in a phase 3 trial, keeping the biotech barreling toward a second readout for its shorter, simpler treatment regimen.
- Acrosian debuts as AI-focused biometrics CROThe founders of contract research organization Quartesian have reunited to form Acrosian, a CRO designed to be purpose-built for the AI era.